Avviso di rettifica
Errata corrige
Errata corrige
Modifica secondaria di un'autorizzazione all'immissione in commercio di medicinale per uso umano. Modifica apportata ai sensi del Regolamento 1234/2008/CE Titolare AIC: B. Braun Avitum AG. Medicinale DUOSOL Soluzione per emofiltrazione AIC 037073 tutte le confezioni Codice Pratica C1B/2017/2965 - Procedura Europea n.: NL/H/0504/001-003/IB/023/G - Tipo di modifica: Type IA- B.II.a.3. b)1.: Description and Composition of the Drug Product: Module 3.2.P.1 Description and Composition of the Drug Product is updated with an upper and lower amount of water for injections. In addition, module 3.2.P.1 is amended with the amount of ingredients of each solution expressed also as mmol/l and with the sentence "The drug product solutions, before and after mixing have the following appearance: Clear and colourless solution, free from visible particles". Type IB - B.II.z): Process validation and/or evaluation: Module 3.2.P.3.5 is updated with regard to the process validation reports for Duosol without Potassium, Duosol with 2 mmol/l Potassium and Duosol with 4 mmol/l Potassium as requested during the Repeat Use Procedure. Type IB - B.II.z):P.3/ P.8 Holding time of bulk solution: Module 3.2.P.3.3 is updated with regard to the holding times for all three strengths: Maximum holding times between the subsequent individual production steps. Preparation of solution until end of filling/sterile filtration: a) holding time of electrolyte solution in closed vessel: 96 h; b) holding time of sodium bicarbonate solution in closed vessel: 10 h. The validation documentation of the holding times has been included in the module 3.2.P.3.5. I lotti gia' prodotti alla data della pubblicazione in GU possono essere mantenuti in commercio fino alla data di scadenza indicata in etichetta ai sensi dell'art. 14 D.L.vo 178/91 e s.m.i. Decorrenza della modifica: dal giorno successivo alla data della sua pubblicazione in G.U. Un procuratore speciale dott.ssa Giuliana Gavioli TX18ADD5463